Nuclear Pharmacy Practice
On-Demand

Nuclear Pharmacy Practice<br>On-Demand

Nuclear Pharmacy Practice
On-Demand

NUCLEAR PHARMACY PRACTICE

Pharmacy and Therapeutics Formulary Process, A Case Study on Sincalide

Jacob Haddock, PharmD, ANP, Oklahoma University Medical Center, Clinical Pharmacist

Upon completion of this activity, pharmacists will be able to: Describe the function and oversight of the pharmacy and therapeutics (P&T) committee; Provide information required by the pharmacy director to add a generic to the formulary; Evaluate a medication for inclusion in the formulary using the example provided.

UAN: 0675-0000-23-024-H04-P

Primer on Potential Theragnostic Agents

Wendy Galbraith, PharmD, FAPhA, BCNP, Clinical Associate Professor, University of Oklahoma, Dept. of Pharmaceutical Sciences, College of Pharmacy, Nuclear Pharmacy & Research Imaging Facility

Upon completion of this activity, pharmacists will be able to: Recall radionuclides for therapy; Describe regulations for therapy radiopharmaceuticals; Identify new radiopharmaceutical therapies in the pipeline.

UAN: 0675-0000-23-025-H04-P

Nuclear Pharmacy:  Departments Questions when 795, 797, and 825 are Official – PART 1   

Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings

Upon completion of this activity, pharmacists will be able to: Describe the treatments available for feline hyperthyroidism; Identify the methods of administration of I-131 solution; Discuss the preparation method of the sterile solution applying principles of radiation safety.

UAN: 0675-0000-23-026-H07-P

Sterile Preparation of I-131 Solution for Feline Hyperthyroidism

Garcia Simon, PharmD, MS, ANP, CCP, BCNP, Kindred Healthcare, Pharmacy Supervisor

Upon completion of this activity, pharmacists will be able to: Describe the treatments available for feline hyperthyroidism; Identify the methods of administration of I-131 solution; Discuss the preparation method of the sterile solution applying principles of radiation safety.

UAN: 0675-0000-23-027-H01-P

Review of the Principles Related to Scintillation Detection of Radioactive Materials

Kara Weatherman, PharmD, FAPhA, BCNP, Clinical Professor & Associate Department Head – Department of Pharmacy Practice, Director – Nuclear Pharmacy Programs, Purdue University

Upon completion of this activity, pharmacists will be able to: Review basic principles of setting up and operating a scintillation detector; Discuss the differences between single and multi-channel detectors; Describe the concept of efficiency and how this relates to accurate determination of radioactivity.

UAN: 0675-0000-23-028-H04-P

F-18 Flurpiridaz Assessment of Myocardial Perfusion-Specific Procedures

Wendy Galbraith, PharmD, FAPhA, BCNP, Clinical Associate Professor, University of Oklahoma, Dept. of Pharmaceutical Sciences, College of Pharmacy, Nuclear Pharmacy & Research Imaging Facility

Upon completion of this activity, pharmacists will be able to: Recall the properties of PET and SPECT MPI tracers; Describe the PET imaging technology used for myocardial imaging; Identify clinical applications for F-18 flurpiridaz.

UAN: 0675-0000-23-029-H01-P

Nuclear Pharmacy: Department Questions when 795, 797, and 825 are Official – PART  2

Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings

Upon completion of this activity, pharmacists will be able to: Describe the changes taking place with the implementation of USP 825, 797, and 795; Identify the additional USP chapters that are applicable to nuclear pharmacy; Discuss how internal procedures and parameters are determined and why they matter.

UAN: 0675-0000-23-030-H07-P

Pharmacist’s Potential Role in Radiopharmaceutical Therapy (RPT)            

Reiko Oyama, MS, RPH, BCNP, Washington University, Director, Nuclear Pharmacy

Upon completion of this activity, pharmacists will be able to: Describe logistical, technical, and radiation safety considerations for implementing a radiopharmaceutical therapy program; List major operating procedures for the RPT example Lu-177-PSMA; Develop your own plan for implementing a radiopharmaceutical therapy program.

UAN: 0675-0000-23-031-H04-P

No Comments

Comments are closed.